It has been shown that downregulating the expression of MAPK1 could enzymatically inhibit the activation of proteins related to IR, such as STAT3, and had been proposed as a valuable candidate target for diabetes treatment. This evidence concerns the gene MAPK1 and diabetes mellitus.